Compass Pathways Selects Fluence for COMP360 Therapy Training

Compass Pathways has selected the clinical training firm Fluence to develop an educational curriculum for its investigational psilocybin therapy, COMP360. The company is preparing for potential FDA authorization. This partnership creates a standardized training framework for healthcare providers, although the program remains contingent on regulatory approval.

"This is a moment Fluence has been preparing for since our earliest days," said Elizabeth Nielson, PhD, Chief Executive Officer and Co-Founder of Fluence.

Curriculum Structure and Regulatory Context

The training program will be implemented after the FDA grants approval and the therapy becomes commercially available. According to the official announcement, the certificate program includes three modules:

• Foundations of Psychedelic Care: An introduction to the principles of psychedelic-assisted therapy.
• Understanding Psilocybin: A review of the pharmacology and psychological impacts of the compound.
• COMP360 Certification: A module focused on the administration and therapeutic protocols associated with Compass Pathways' proprietary formulation.

Market Reaction

Compass Pathways (NASDAQ: CMPS) shares declined 6.26% on September 10, 2026. Market activity increased during the session, as trading volume reached 2.8 times the company's daily average, according to data from StockTitan.

Why Specialized Training Matters

This curriculum addresses the requirements of psychedelic medicine, which differs from traditional psychiatric pharmacology. Psilocybin therapy requires a structured psychological support environment during the dosing session. By outsourcing the training design to a specialized firm, Compass Pathways intends to ensure clinicians are prepared to handle the safety and efficacy protocols required for the administration of COMP360 in a post-approval clinical setting.